NCT01079325View on ClinicalTrials.gov

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

May 31, 2015

Study Completion Date

April 30, 2016

Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic Polyneuropathy
Interventions
DRUG

SB-509

SB-509 60 mg, 3 treatments, and 5 months treatment period

OTHER

Saline

Trial Locations (31)

Unknown

Phoenix

Scottsdale

Tucson

Chino

Fresno

La Jolla

Los Angeles

National City

San Francisco

Walnut Creek

Boulder

DeLand

Fort Myers

Miami

Orlando

Tampa

West Palm Beach

Idaho Falls

Meridian

Lexington

Boston

Kansas City

Las Vegas

Winston-Salem

Tulsa

Greer

Dallas

Houston

San Antonio

Salt Lake City

Norfolk

Sponsors
All Listed Sponsors
collaborator

Juvenile Diabetes Research Foundation

OTHER

lead

Sangamo Therapeutics

INDUSTRY